NGM120 treatment for cachexia in colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial testing NGM120 in people with colorectal cancer who have cancer cachexia. Participants are randomized to receive NGM120 every 4 weeks, NGM120 every 8 weeks, or placebo, with treatment and follow-up visits to measure efficacy, safety, and tolerability. Key eligibility includes an active diagnosis of colorectal cancer and cachexia defined by the Fearon criteria, while exclusions include reversible causes of poor intake and current tube or parenteral feeding. Study sites are operated by NGM Biopharmaceuticals and are located in California, requiring in-person visits for dosing and monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Documented active diagnosis of colorectal cancer.
2. Cachexia defined by Fearon criteria of weight loss.
3. Signed informed consent.

Exclusion Criteria:

1. Current active reversible causes of decreased food intake.
2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
3. Have cachexia caused by other reasons.

Where it's running

• NGM Clinical Study Site
  Los Angeles, California, United States Recruiting
• NGM Clinical Study Site
  Los Angeles, California, United States Recruiting
• NGM Clinical Study Site
  Santa Rosa, California, United States Recruiting
• NGM Clinical Study Site
  Margate, Florida, United States Recruiting
• NGM Clinical Study Site
  Baltimore, Maryland, United States Recruiting
• NGM Clinical Study Site
  New York, New York, United States Recruiting

Study contacts

• Study coordinator: NGM Study Director
• Email: NGM120CX@ngmbio.com
• Phone: 650-727-8800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining muscle characteristics in colorectal cancer patients with cachexia

  This study looks at the muscles of colorectal cancer patients with and without cachexia to see how they differ from healthy people.

  Recruiting at 2 sites Hasselt University · Diepenbeek, Limburg and 1 other locations · NCT06780423

• Knife-assisted full-thickness resection for rectal lesions in a multicenter setting

  A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.

  Recruiting University Hospital, Ghent · Ghent · NCT07923682

• Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model

  This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.

  Recruiting Peking Union Medical College Hospital · Ningbo, Zhejiang · NCT07919418

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.